Literature DB >> 19048188

A multimodal strategy based on surgery, radiotherapy, ICE regimen and high dose chemotherapy in atypical teratoid/rhabdoid tumours: a single institution experience.

Paola Fidani1, Maria Antonietta De Ioris, Annalisa Serra, Luigi De Sio, Ilaria Ilari, Raffaele Cozza, Renata Boldrini, Giuseppe Maria Milano, Maria Luisa Garrè, Alberto Donfrancesco.   

Abstract

PURPOSE: Atypical Teratoid/Rhabdoid Tumour is a rare and aggressive childhood tumour. The outcome of a series treated with the same multimodal strategy was reported. PATIENTS: The patients were treated with surgery, 2 courses of ifosfamide/carboplatin/etoposide(ICE), 2 courses of cyclophosphamide/etoposide/carboplatino/thiotepa (CECAT) or 2 other ICE courses, high dose chemotherapy (HDC) and radiotherapy.
RESULTS: Eight patients underwent primary surgery achieving a complete removal in 3. Progressive disease (PD) occurred in 2/8 patients during ICE courses and in 3/4 during CECAT courses. After 4 courses 5 patients presented a PD. HDC was performed in 3 patients followed by local radiotherapy. The Kaplan Meier OS and EFS probability at 5 years are, respectively, 50% (CI 11-80%) and 33% (CI 6-66%).
CONCLUSION: A strategy based on surgery, including a second surgical look, and on radiotherapy appears the best option. ICE regimen and HDC correlate with good prognosis in some patients but this approach needs further evaluation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19048188     DOI: 10.1007/s11060-008-9750-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  13 in total

1.  Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype.

Authors:  Christine Haberler; Ute Laggner; Irene Slavc; Thomas Czech; Inge M Ambros; Peter F Ambros; Herbert Budka; Johannes A Hainfellner
Journal:  Am J Surg Pathol       Date:  2006-11       Impact factor: 6.394

Review 2.  Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor.

Authors:  Mary Ann Zimmerman; Liliana C Goumnerova; Mark Proctor; R Michael Scott; Karen Marcus; Scott L Pomeroy; Christopher D Turner; Susan N Chi; Christine Chordas; Mark W Kieran
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

3.  Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.

Authors:  Tanya M Tekautz; Christine E Fuller; Susan Blaney; Maryam Fouladi; Alberto Broniscer; Thomas E Merchant; Matthew Krasin; James Dalton; Gregory Hale; Larry E Kun; Dana Wallace; Richard J Gilbertson; Amar Gajjar
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

4.  Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors.

Authors:  Jaclyn A Biegel; Lu Tan; Fan Zhang; Luanne Wainwright; Pierre Russo; Lucy B Rorke
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

Review 5.  Atypical teratoid/rhabdoid tumors of the central nervous system.

Authors:  Alyssa T Reddy
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

6.  Mutations of the INI1 rhabdoid tumor suppressor gene in medulloblastomas and primitive neuroectodermal tumors of the central nervous system.

Authors:  J A Biegel; B Fogelgren; J Y Zhou; C D James; A J Janss; J C Allen; D Zagzag; C Raffel; L B Rorke
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

Review 7.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

8.  Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry.

Authors:  Joanne M Hilden; Sharon Meerbaum; Peter Burger; Jonathan Finlay; Anna Janss; Bernd W Scheithauer; Andrew W Walter; Lucy B Rorke; Jaclyn A Biegel
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

9.  Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop.

Authors:  Roger J Packer; Jaclyn A Biegel; Susan Blaney; Jonathan Finlay; J Russell Geyer; Richard Heideman; Joanne Hilden; Anna J Janss; Larry Kun; Gilbert Vezina; Lucy B Rorke; Malcolm Smith
Journal:  J Pediatr Hematol Oncol       Date:  2002 Jun-Jul       Impact factor: 1.289

10.  Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity.

Authors:  L B Rorke; R J Packer; J A Biegel
Journal:  J Neurosurg       Date:  1996-07       Impact factor: 5.115

View more
  13 in total

Review 1.  Biology and Treatment of Rhabdoid Tumor.

Authors:  James I Geller; Jacquelyn J Roth; Jaclyn A Biegel
Journal:  Crit Rev Oncog       Date:  2015

2.  Pediatric non-Wilms' renal tumors: a third world experience.

Authors:  Peter W Saula; G P Hadley
Journal:  World J Surg       Date:  2012-03       Impact factor: 3.352

3.  Overall Survival of Primary Intracranial Atypical Teratoid Rhabdoid Tumor Following Multimodal Treatment: A Pooled Analysis of Individual Patient Data.

Authors:  Xiu-Jian Ma; Da Li; Liang Wang; Shu-Yu Hao; Li-Wei Zhang; Jun-Ting Zhang; Zhen Wu
Journal:  Neurosurg Rev       Date:  2018-12-08       Impact factor: 3.042

4.  High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB).

Authors:  M Benesch; K Bartelheim; G Fleischhack; B Gruhn; P G Schlegel; O Witt; K D Stachel; H Hauch; C Urban; F Quehenberger; M Massimino; T Pietsch; M Hasselblatt; F Giangaspero; U Kordes; R Schneppenheim; P Hauser; T Klingebiel; M C Frühwald
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

5.  Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.

Authors:  Seung Ah Choi; Jung Won Choi; Kyu-Chang Wang; Ji Hoon Phi; Ji Yeoun Lee; Kyung Duk Park; Dayoung Eum; Sung-Hye Park; Il Han Kim; Seung-Ki Kim
Journal:  Neuro Oncol       Date:  2014-11-04       Impact factor: 12.300

6.  Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors.

Authors:  Lindsey M Hoffman; Elizabeth Anne Richardson; Ben Ho; Ashley Margol; Alyssa Reddy; Lucie Lafay-Cousin; Susan Chi; Irene Slavc; Alexander Judkins; Martin Hasselblatt; Franck Bourdeaut; Michael C Frühwald; Rajeev Vibhakar; Eric Bouffet; Annie Huang
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

Review 7.  Rare Primary Central Nervous System Tumors Encountered in Pediatrics.

Authors:  Kim Kramer
Journal:  J Child Neurol       Date:  2016-01-22       Impact factor: 1.987

Review 8.  Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature.

Authors:  D Schrey; F Carceller Lechón; G Malietzis; L Moreno; C Dufour; S Chi; L Lafay-Cousin; K von Hoff; T Athanasiou; L V Marshall; S Zacharoulis
Journal:  J Neurooncol       Date:  2015-11-25       Impact factor: 4.130

9.  Outcomes with respect to extent of surgical resection for pediatric atypical teratoid rhabdoid tumors.

Authors:  Alexandra Richards; Ronak Ved; Christopher Murphy; Dawn Hennigan; John-Paul Kilday; Ian Kamaly-Asl; Conor Mallucci; Imran Bhatti; Chirag Patel; Paul Leach
Journal:  Childs Nerv Syst       Date:  2019-12-31       Impact factor: 1.475

10.  Atypical teratoid rhabdoid tumor: current therapy and future directions.

Authors:  Kevin F Ginn; Amar Gajjar
Journal:  Front Oncol       Date:  2012-09-12       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.